BACKGROUND: Absence of clinical and radiological activity in relapsing-remitting multiple sclerosis (RRMS) is perceived as disease remission. We explored the role of persisting inflammation during remission in disease evolution. METHODS: Cerebrospinal fluid (CSF) levels of interleukin 1beta (IL-1beta), a major proinflammatory cytokine, were measured in 170 RRMS patients at the time of clinical and radiological remission. These patients were then followed up for at least 4 years, and clinical, magnetic resonance imaging (MRI) and optical coherence tomography (OCT) measures of disease progression were recorded. RESULTS: Median follow-up of RRMS patients was 5 years. Detection of CSF IL-1beta levels at the time of remission did not predict earlier relapse or new MRI lesion formation. Detection of IL-1beta in the CSF was instead associated with higher progression index (PI) and Multiple Sclerosis Severity Scale (MSSS) scores at follow-up, and the number of patients with sustained Expanded Disability Status Scale (EDSS) or Multiple Sclerosis Functional Composite worsening at follow-up was higher in individuals with detectable levels of IL-1beta. Patients with undetectable IL-1beta in the CSF had significantly lower PI and MSSS scores and a higher probability of having a benign MS phenotype. Furthermore, patients with undetectable CSF levels of IL-1beta had less retinal nerve fiber layer thickness and macular volume alterations visualized by OCT compared to patients with detectable IL-1beta. CONCLUSIONS: Our results suggest that persistence of a proinflammatory environment in RRMS patients during clinical and radiological remission influences midterm disease progression. Detection of IL-1beta in the CSF at the time of remission appears to be a potential negative prognostic factor in RRMS patients.
Rossi, S., Studer, V., Motta, C., Germani, G., Macchiarulo, G., Buttari, F., et al. (2014). Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis. JOURNAL OF NEUROINFLAMMATION, 11(1), 32-32 [10.1186/1742-2094-11-32].
|Tipologia:||Articolo su rivista|
|Citazione:||Rossi, S., Studer, V., Motta, C., Germani, G., Macchiarulo, G., Buttari, F., et al. (2014). Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis. JOURNAL OF NEUROINFLAMMATION, 11(1), 32-32 [10.1186/1742-2094-11-32].|
|IF:||Con Impact Factor ISI|
|Settore Scientifico Disciplinare:||Settore MED/26 - Neurologia|
|Revisione (peer review):||Esperti anonimi|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1186/1742-2094-11-32|
|Stato di pubblicazione:||Pubblicato|
|Data di pubblicazione:||18-feb-2014|
|Titolo:||Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis|
|Autori:||Rossi, S; Studer, V; Motta, C; Germani, G; Macchiarulo, G; Buttari, F; Mancino, R; Castelli, M; De Chiara, V; Weiss, S; Martino, G; Furlan, R; Centonze, D|
|Appare nelle tipologie:||01 - Articolo su rivista|
File in questo prodotto:
|Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis..pdf||N/A||Copyright dell'editore||UNIVERSITY_NETWORK Richiedi una copia|